mAbxience S.L.

Amneal is looking ahead to a US Food and Drug Administration target action date in the fourth quarter of 2025 for its proposed mAbxience-partnered Prolia/Xgeva (denosumab) biosimilars, after they were

Two biosimilar candidates developed by mAbxience will be commercialized in key central and eastern European territories by Egis, under a strategic licensing deal that has just been struck between the

Teva’s commitment to continue upsizing its existing pipeline of biosimilars, with a continued preference for partnerships, is continuing apace. The Israeli firm has penned a licensing agreement with

Intas and biosimilars specialist mAbxience have struck a licensing deal covering mAbxience’s proposed biosimilar to Enbrel (etanercept), giving Intas exclusive commercialization rights to the candi